UT gains oral Trep approval.

Quote












Anonymous said:
Anonymous said:
Wow, that must

Not quite.

Oral trep label will be horrendous. The dosing / titration will keep most from ever using It on a regular basis. Oral tre will be the last oral option unless you want to transition someone from Tyvaso or Remodulin to an oral medication.
Click to expand...

That's where the Drs will get their trial starts but then it may takeoff as 2nd line to ERAs
Click to expand...
 












Keep telling yourself that with you horrendous data on Maci? Drug is a joke and bought and paid for physicians are the only ones backing it! Every PAH physician loves the prostacyclin pathways so oral trep will be big!
Also Why did uthr go up 20 bucks on approval? Wallstreet is always wrong in your opinion but then again that's why your stock is still on the Swiss exchange no one in America gives a shit!
 












The product is soooo bad that even UT wasn't prepared for an early approval. 4-6 months before the drug is available will give me plenty of time to make sure the doctors are aware of all of the issues with the drug. I wouldn't want them to be caught off guard. lol. My KOLs said that they will try it as an option before inhaled, sub-q, or IV therapy. But that they would only give it a small window to work. While Maci may lose about 2-5 enrollments a week initially, this drug will end up hurting Tyvaso. By initially I mean the first month. We will make sure that it is DOA before it is available. Enjoy while you can because when your launch fails consider how your upper management will respond.
 






Anonymous said:
The product is soooo bad that even UT wasn't prepared for an early approval. 4-6 months before the drug is available will give me plenty of time to make sure the doctors are aware of all of the issues with the drug. I wouldn't want them to be caught off guard. lol. My KOLs said that they will try it as an option before inhaled, sub-q, or IV therapy. But that they would only give it a small window to work. While Maci may lose about 2-5 enrollments a week initially, this drug will end up hurting Tyvaso. By initially I mean the first month. We will make sure that it is DOA before it is available. Enjoy while you can because when your launch fails consider how your upper management will respond.
Click to expand...

Why are you worried? The titration schedule, the side effect profile, and the weak clinical trial data is going to scare away all but the UT bought and paid MD's.
 






Don't worry Maci will set its own path to failure. How many of Val and Channicks patients will come back ask to be put back on Tracleer cause it is a better drug than Maci! Patients will eventually want to be on a medication that works not one that the physician writes because of payments.
 






Anonymous said:
Don't worry Maci will set its own path to failure. How many of Val and Channicks patients will come back ask to be put back on Tracleer cause it is a better drug than Maci! Patients will eventually want to be on a medication that works not one that the physician writes because of payments.
Click to expand...

Generic ERA vs next Generation- expensive ERA in this economy, well it may come down to $.
 
























Top Bottom
Back
Quote